Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1175-1181

  Vidal Jordana, Angela ^a   Sastre Garriga, Jaume ^a   Pérez Miralles, Francisco ^a   Tur, Carmen ^a   Tintoré, Mar ^a   Horga, Alejandro ^a   Auger, Cristina ^a   Río, Jordi ^a   Nos, Carlos ^a   Edo, Mari C ^a   Arévalo, María J ^a   Castilló, Joaquín ^a   Rovira, Alex ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

brain atrophy; brain MRI; brain volume; drug side effects; monoclonal antibody therapy; Multiple sclerosis; natalizumab; pseudoatrophy; white matter

Indexed keywords

GADOLINIUM; NATALIZUMAB;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; WHITE MATTER LESION;

BRAIN ATROPHY; BRAIN MRI; BRAIN VOLUME; DRUG SIDE EFFECTS; MONOCLONAL ANTIBODY THERAPY; MULTIPLE SCLEROSIS; NATALIZUMAB; PSEUDOATROPHY; WHITE MATTER;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATROPHY; BRAIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE FIBERS, MYELINATED;

EID: 84881032710     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512473190     Document Type: Article

References (29)

1. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006 ; 5: 158-170
2. De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy in multiple sclerosis. J Neuroimag. 2007 ; 17: 10S - 15S
3. Rudick RA. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimag. 2004 ; 14: 54S - 64S
4. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurol. 2008 ; 71: 136-144
5. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurol 2007. 68: 1390-1401
6. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011 ; 17: 708-719
7. Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol. 2011 ; 52: 321-330
8. Mancardi GL, Tedeschi G, Amato MP, et al. Three years of experience: The Italian registry and safety data update. Neurol Sci. 2011 ; 31: 295-297
9. Oturai AB, Koch-Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study. Eur J Neurol. 2009 ; 16: 420-423
10. Putzki N, Yaldizli O, Buhler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: Results from a multicenter study in Switzerland. Eur Neurol. 2010 ; 63: 101-106
11. Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study. Neurol Sci. 2011 ; 31: 299-302
12. Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: Results from a multi-center study in German speaking countries. Eur J Neurol. 2010 ; 17: 31-37
13. European Medicines Agency. Product information of natalizumab. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000603/WC500044686.pdf. Last accessed: October 2012.
14. Smith SM, De Stefano N, Jenkinson M, et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001 ; 25: 466-475
15. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage. 2000 ; 11: 805-821
16. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 ; 359: 1221-1231
17. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurol. 2002 ; 59: 1412-1420
18. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurol. 1999 ; 53: 139-148
19. Richert ND, Howard T, Frank JA, et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurol 2006. 66: 551-556
20. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285
21. De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol. 2002 ; 59: 1565-1571
22. Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: A 14-year followup study. J Neurol Neurosurg Psychiatry. 2003 ; 74: 1551-1554
23. Saindane AM, Ge Y, Udupa JK, et al. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurol. 2000 ; 55: 61-65
24. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurol. 64: 236-240
25. Cheriyan J, Kim S, Wolansky LJ, et al. Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol. 2012 ; 69: 82-88
26. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: A longitudinal study. Brain. 2005 ; 128: 1454-1460
27. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: A 2-year longitudinal study. Neurol. 2005 ; 64: 1001-1007
28. Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler. 2012 ; 18: 418-424
29. Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler. 2007 ; 13: 490-501